Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon

Journal of Controlled Release

Volumn 178, Issue 1, 2014, Pages 46-54

  Hou, Huiyuan ^a,b   Nieto, Alejandra ^a,b   Ma, Feiyan ^a   Freeman, William R ^a   Sailor, Michael J ^b   Cheng, Lingyun ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Controlled drug release; Daunorubicin; Intravitreal drug delivery; Porous silicon; Rabbit eye

Indexed keywords

CONTROLLED DRUG RELEASE; DAUNORUBICIN; DISSOLUTION CHAMBERS; DRUG DELIVERY SYSTEM; ETCHING PARAMETERS; NEO-VASCULARIZATION; OXIDIZED POROUS SILICON; RABBIT EYE;

DISSOLUTION; DRUG DELIVERY; NANOPORES; PORE SIZE; POROUS SILICON;

CARBON DIOXIDE;

DAUNORUBICIN; SILICON; SILICON DIOXIDE;

ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL ACTIVITY; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DEGRADATION; DISSOLUTION; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MODULATION; NONHUMAN; PARTICLE SIZE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; VITREOUS BODY;

3-AMINOPROPYLTRIETHOXYSILANE; CONTROLLED DRUG RELEASE; DAUNORUBICIN; DAUNORUBICIN HYDROCHLORIDE; ETHANOL; HYDROFLUORIC ACID; INTRAVITREAL DRUG DELIVERY; N,N-DIMETHYLFORMAMIDE; N-(3-DIMETHYLAMINOPROPYL)-N'-ETHYLCARBODIIMIDE HYDROCHLORIDE; NITROGEN; POROUS SILICON; RABBIT EYE; SILICON; SILICON DIOXIDE; SUCCINIC ANHYDRIDE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; CELL PROLIFERATION; DAUNORUBICIN; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; INTRAVITREAL INJECTIONS; OXIDATION-REDUCTION; POROSITY; RABBITS; SILICON; VITREOUS BODY;

EID: 84893444417     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.01.003     Document Type: Article

References (33)

1. W. Berger, B. Kloeckener-Gruissem, and J. Neidhardt The molecular basis of human retinal and vitreoretinal diseases Prog. Retin. Eye Res. 29 2010 335 375
2. L. Cheng, K. Hostetler, N. Valiaeva, A. Tammewar, W.R. Freeman, J. Beadle, D.U. Bartsch, K. Aldern, and I. Falkenstein Intravitreal crystalline drug delivery for intraocular proliferation diseases Invest. Ophthalmol. Vis. Sci. 51 2010 474 481
3. G.A. Peyman, and J. Schulman Proliferative vitreoretinopathy and chemotherapeutic agents Surv. Ophthalmol. 29 1985 434 442 (Pubitemid 15040351)
4. K. Shinohara, M. Tanaka, T. Sakuma, and Y. Kobayashi Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy Ophthalmic Surg. Lasers Imaging 34 2003 299 305 (Pubitemid 36869622)
5. J.A. Khawly, P. Saloupis, D.L. Hatchell, and R. Machemer Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy Graefes Arch. Clin. Exp. Ophthalmol. 229 1991 464 467
6. P. Wiedemann, R.D. Hilgers, P. Bauer, and K. Heimann Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group Am J. Ophthalmol. 126 1998 550 559 (Pubitemid 28475919)
7. A. Kumar, S. Nainiwal, I. Choudhary, H.K. Tewari, and L.K. Verma Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery Clin. Exp. Ophthalmol. 30 2002 348 351 (Pubitemid 35203373)
8. P. Wiedemann, N. Sorgente, C. Bekhor, R. Patterson, T. Tran, and S.J. Ryan Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo Invest. Ophthalmol. Vis. Sci. 26 1985 719 725 (Pubitemid 15067813)
9. L. Cheng, E. Anglin, F. Cunin, D. Kim, M.J. Sailor, I. Falkenstein, A. Tammewar, and W.R. Freeman Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle Br. J. Ophthalmol. 92 2008 705 711 (Pubitemid 351684186)
10. J. Chhablani, A. Nieto, H. Hou, E.C. Wu, W.R. Freeman, M.J. Sailor, and L. Cheng Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system Invest. Ophthalmol. Vis. Sci. 54 2013 1268 1279
11. K.I. Hartmann, A. Nieto, E.C. Wu, W.R. Freeman, J.S. Kim, J. Chhablani, M.J. Sailor, and L. Cheng Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin J. Ocul. Pharmacol. Ther. 29 2013 493 500
12. A. Nieto, H. Hou, M.J. Sailor, W.R. Freeman, and L. Cheng Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles Exp. Eye Res. 116 2013 161 168
13. S.H.C. Anderson, H. Elliott, D.J. Wallis, L.T. Canham, and J.J. Powell Dissolution of different forms of partially porous silicon wafers under simulated physiological conditions Phys. Status Solidi A 197 2003 331 335
14. J.O. Martinez, C. Chiappini, A. Ziemys, A.M. Faust, M. Kojic, X. Liu, M. Ferrari, and E. Tasciotti Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics Biomaterials 34 2013 8469 8477
15. M.J. Sailor Porous Silicon in Practice: Preparation, Characterization, and Applications 2012 Wiley-VCH
16. E.C. Wu, J.S. Andrew, A. Buyanin, J.M. Kinsella, and M.J. Sailor Suitability of porous silicon microparticles for the long-term delivery of redox-active therapeutics Chem. Commun. (Camb.) 47 2011 5699 5701
17. E.C. Wu, J.H. Park, J. Park, E. Segal, F. Cunin, and M.J. Sailor Oxidation-triggered release of fluorescent molecules or drugs from mesoporous Si microparticles ACS Nano 2 2008 2401 2409
18. C. Pacholski, M. Sartor, M.J. Sailor, F. Cunin, and G.M. Miskelly Biosensing using porous silicon double-layer interferometers: reflective interferometric Fourier transform spectroscopy J. Am. Chem. Soc. 127 2005 11636 11645 (Pubitemid 41208748)
19. K.S.W., and S.J.S. Gregg Adsorption, Surface Area and Porosity 2nd ed. 1982 Academic Press Inc. London
20. E.P. Brunauer S., and E. Teller Adsorption of gases in multimolecular layers J. Am. Chem. Soc. 60 1938 309 319
21. M. Kruk, M. Jaroniec, and A. Sayari Relations between pore structure parameters and their implications for characterization of MCM-41 using gas adsorption and X-ray diffraction Chem. Mater. 11 1999 492 500 (Pubitemid 129687535)
22. J.S. Kim, J.R. Beadle, W.R. Freeman, K.Y. Hostetler, K. Hartmann, N. Valiaeva, I. Kozak, L. Conner, J. Trahan, K.A. Aldern, and L. Cheng A novel cytarabine crystalline lipid prodrug: hexadecyloxypropyl cytarabine 3′,5′-cyclic monophosphate for proliferative vitreoretinopathy Mol. Vis. 18 2012 1907 1917
23. L.Y. Cheng, K.Y. Hostetler, M.F. Gardner, C.P. Avila, G. Bergeron-Lynn, G.M. Severson, and W.R. Freeman Intravitreal pharmacokinetics in rabbits of the foscarnet lipid prodrug: 1-O-octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA) Curr. Eye Res. 18 1999 161 167 (Pubitemid 29213830)
24. U. Bartz-Schmidt, P. Szurman, D. Wong, and B. Kirchhof New developments in retinal detachment surgery Ophthalmologe 105 2008 27 36
25. S. Scheer, C. Morel, O. Touzeau, J.A. Sahel, and L. Laroche Pharmacological adjuvants for surgical treatment of proliferative vitreoretinopathy J. Fr. Ophtalmol. 27 2004 1051 1059 (Pubitemid 39556836)
26. P. Wiedemann, M. Kirmani, M. Santana, N. Sorgente, and S.J. Ryan Control of experimental massive periretinal proliferation by daunomycin: dose-response relation Graefes Arch. Clin. Exp. Ophthalmol. 220 1983 233 235 (Pubitemid 13037305)
27. M. Santana, P. Wiedemann, M. Kirmani, D.S. Minckler, R. Patterson, N. Sorgente, and S.J. Ryan Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit Graefes Arch. Clin. Exp. Ophthalmol. 221 1984 210 213 (Pubitemid 14114986)
28. J. Hou, Y. Li, Z. Zhou, N. Valiaeva, J.R. Beadle, K. Hostetler, W.R. Freeman, D.N. Hu, H. Chen, and L. Cheng Antiproliferative property of hexadecyloxypropyl 9-[2-(phosphonomethoxy) ethyl] guanine (HDP-PMEG) for unwanted ocular proliferation Mol. Vis. 17 2011 627 637
29. M.H. Rahimy, G.A. Peyman, M.L. Fernandes, S.H. el-Sayed, Q. Luo, and H. Borhani Effects of an intravitreal daunomycin implant on experimental proliferative vitreoretinopathy: simultaneous pharmacokinetic and pharmacodynamic evaluations J. Ocul. Pharmacol. 10 1994 561 570 (Pubitemid 24321155)
30. E.J. Anglin, L. Cheng, W.R. Freeman, and M.J. Sailor Porous silicon in drug delivery devices and materials Adv. Drug Deliv. Rev. 60 2008 1266 1277
31. C.D. Regillo, D.M. Brown, P. Abraham, H. Yue, T. Ianchulev, S. Schneider, and N. Shams Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J. Ophthalmol. 145 2008 239 248
32. H. Davson, and C.P. Luck Chemistry and rate of turnover of the ocular fluids of the bush baby (Galago crassicaudatus Agisymbanus) J. Physiol. 145 1959 433 439
33. G. Zhang Porous silicon: morphology and formation mechanisms Mod. Asp. Electrochem. 39 2006 65 133